MetaCap

Protalix BioTherapeutics Inc. (DE) (PLX)

NYSE: PLXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.90-0.16 (-5.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PLX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$244.52M
52-week range
1.65 – 3.19
Day range
2.87 – 3.04
Volume / Avg
1.23M / 903.48K
Beta
—

52-week range

$1.65$3.19

PLX stock today

Protalix BioTherapeutics (DE) (PLX) closed at $2.90 on Nov 20, down 5.23% (-$0.16), versus the S&P 500's 3.70% decline. At this level, PLX sits near the top of its 52-week range of $1.65 to $3.19: 9.1% below the high, set on Feb 23, 2026 and 75.8% above the low. PLX is up 61.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 65.7%.

Protalix BioTherapeutics (DE) trades at 12.1x its trailing twelve-month earnings per share of $0.24. Its forward P/E of 4.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Protalix BioTherapeutics (DE)

Company profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Dror Bashan
Headquarters
Hackensack, NJ
Employees
226

Financial highlights

Full financials

In fiscal 2025, Protalix BioTherapeutics (DE) generated $52.7 million in revenue, down 1.2% from fiscal 2024, its first annual decline since 2024. Protalix BioTherapeutics (DE) reported a net loss of $6.6 million, compared with net income of $2.9 million a year earlier. Gross margin was 48.8% (down from 54.5%) and operating margin -10.4%.

Protalix BioTherapeutics (DE) annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$52.74M$53.40M$65.49M$47.64M$38.35M
Growth-1.23%-18.47%+37.48%+24.22%-39.03%
Net income$-6.60M$2.93M$8.31M$-14.93M$-27.58M
EPS (diluted)$-0.08$0.04$0.09$-0.31$-0.62

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$12.00+313.79%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$0.05 vs $-0.02
Surprise
+350.00%

PLX news

All PLX news

Protalix BioTherapeutics (DE) peers

Health Care sector
PLX peer companies
CompanyPrice% ChgMarket capCompare
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs PLX
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs PLX
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs PLX
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs PLX
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs PLX
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs PLX
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs PLX
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs PLX

Indexes, lists and sector

Protalix BioTherapeutics (DE) stock FAQ

What is Protalix BioTherapeutics (DE)'s stock price today?

PLX last traded at $2.90 as of Nov 20, 4:00 PM EST, down 5.23% on the day. Prices are delayed at least 15 minutes.

Does Protalix BioTherapeutics (DE) pay a dividend?

No. Protalix BioTherapeutics (DE) does not currently pay a regular cash dividend.

What is PLX's P/E ratio?

PLX trades at a trailing P/E ratio of 12.08 and a forward P/E of 4.68.

Who is Protalix BioTherapeutics (DE)'s CEO?

Mr. Dror Bashan is the chief executive officer of Protalix BioTherapeutics Inc. (DE), which has about 226 employees.

Has PLX ever split its stock?

Yes. The most recent PLX stock split was a 1-for-10 split on Dec 20, 2019, one of 2 splits on record.

What is the PLX 52-week high?

The 52-week high for PLX is $3.19 and the 52-week low is $1.65. The stock is currently 9.1% below its high.

Compare PLX